Technology areas: Biotechnology & Pharmaceuticals • Chemistry & Materials
10 pending office actions • 10 art units • 10 examiners • 0 of 10 (0%) have an AI response strategy ready • 31 patents granted in the last 365 days
Jiangnan University has 10 pending office actions in Biotechnology & Pharmaceuticals. The matters span 10 distinct examiners and 10 distinct art units, showing complete distribution across the listed examination assignments. No art unit or examiner grouping is identified as a recurring concentration.
IPPOLITO, NICOLE MARIE is the busiest examiner, with 1 pending matter. The evenly distributed structure makes a centralized technical framework useful for consistency, but it does not support treating one examiner's approach as representative of the portfolio.
Counsel should organize prosecution by matter while maintaining a shared record of scientific definitions, claim terminology, and recurring disclosure positions. Separate examiner and art-unit tracking is important because each action has its own examination context. Interviews, amendments, and responses should be scheduled and evaluated independently, with cross-matter coordination used only where the underlying technology and claim language genuinely overlap.
Based on the USPTO statutory response window for each pending office action. 3 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 3 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (10%) |
| §103 only | 5 (50%) |
| §102 only | 1 (10%) |
| §112 only | 2 (20%) |
| Multi-statute (no §101) | 1 (10%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| IPPOLITO, NICOLE MARIE | 1 | 86.7% | +9.5% |
| ZILBERING, ASSAF | 1 | 35.3% | +27.6% |
| GALSTER, SAMUEL LEONARD | 1 | 52.1% | +42.2% |
| MCCLENDON, SANZA L | 1 | 80.4% | +10.7% |
| SKOKO III, JOHN JOSEPH | 1 | 53.0% | +55.2% |
| ZEMAN, ROBERT A | 1 | 54.2% | +27.9% |
| MORENO, LARK JULIA | 1 | 0.0% | +0.0% |
| LEBLANC, KATHERINE DEGUIRE | 1 | 34.6% | +36.0% |
| EIX, EMILY FAY | 1 | 45.7% | +76.0% |
| MAHLUM, JONATHAN DAVIS | 1 | 50.0% | +23.3% |
Cases in front of an examiner with an allow rate of 80%+ where the difficulty is Easy or Medium. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18920143 | Oligosaccharide-Fluorescent Marker, and Preparation Method and Use thereof | IPPOLITO, NICOLE MARIE | — |
| 18457642 | METHOD FOR PREPARING METAL INK AND ADDITIVE MANUFACTURING BASED ON PHOTO-THERMAL SYNERGISTIC CURING | MCCLENDON, SANZA L | — |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18584708 | NON-ANIMAL CHONDROITIN SULFATE OLIGOSACCHARIDE AND PREPARATION METHOD THEREOF | GALSTER, SAMUEL LEONARD | — |
| 18188554 | Aquatic-plant Protein Combined Restructured Meat and Preparation Method thereof | MORENO, LARK JULIA | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17990976 | Application of microbiota-derived plasmalogens to Treatment of Colon Cancer | MAHLUM, JONATHAN DAVIS | 16d overdue |
| 18337631 | ANTIBODY CONJUGATE AND METHOD FOR ENHANCING IMMUNE EFFECT FUNCTION OF ANTIBODY MOLECULE | SKOKO III, JOHN JOSEPH | 14d |
| 18191919 | Bifidobacterium longum for Preventing and/or Treating Essential Hypertension | ZEMAN, ROBERT A | 63d |
| 18811929 | Oil Crystallization Promoter, Preparation Method Therefor and Use Thereof | ZILBERING, ASSAF | — |
| 18584708 | NON-ANIMAL CHONDROITIN SULFATE OLIGOSACCHARIDE AND PREPARATION METHOD THEREOF | GALSTER, SAMUEL LEONARD | — |
| 18457642 | METHOD FOR PREPARING METAL INK AND ADDITIVE MANUFACTURING BASED ON PHOTO-THERMAL SYNERGISTIC CURING | MCCLENDON, SANZA L | — |
| 18075454 | METHOD FOR PREPARING PROTEIN NANOPARTICLE MICROSPHERES | LEBLANC, KATHERINE DEGUIRE | — |
| 18061585 | Genetically Engineered Bacteria Producing Lacto-N-neotetraose and Production Method Thereof | EIX, EMILY FAY | — |
| Art Unit | Apps |
|---|---|
| 2881 | 1 |
| 1792 | 1 |
| 1693 | 1 |
| 1765 | 1 |
| 1643 | 1 |
| 1645 | 1 |
| 1793 | 1 |
| 1791 | 1 |
| 1653 | 1 |
| 1625 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18920143 | Oligosaccharide-Fluorescent Marker, and Preparation Method and Use thereof | IPPOLITO, NICOLE MARIE | 2881 | §102 | Non-Final OA | — | Pending | Oct 18, 2024 |
| 18811929 | Oil Crystallization Promoter, Preparation Method Therefor and Use Thereof | ZILBERING, ASSAF | 1792 | §103 | Non-Final OA | — | Pending | Aug 22, 2024 |
| 18584708 | NON-ANIMAL CHONDROITIN SULFATE OLIGOSACCHARIDE AND PREPARATION METHOD THEREOF | GALSTER, SAMUEL LEONARD | 1693 | §101§102§103§112 | Non-Final OA | — | Pending | Feb 22, 2024 |
| 18457642 | METHOD FOR PREPARING METAL INK AND ADDITIVE MANUFACTURING BASED ON PHOTO-THERMAL SYNERGISTIC CURING | MCCLENDON, SANZA L | 1765 | §112 | Final Rejection | — | Pending | Aug 29, 2023 |
| 18337631 | ANTIBODY CONJUGATE AND METHOD FOR ENHANCING IMMUNE EFFECT FUNCTION OF ANTIBODY MOLECULE | SKOKO III, JOHN JOSEPH | 1643 | §103 | Final Rejection | 14d | Pending | Jun 20, 2023 |
| 18191919 | Bifidobacterium longum for Preventing and/or Treating Essential Hypertension | ZEMAN, ROBERT A | 1645 | §112 | Non-Final OA | 63d | Pending | Mar 29, 2023 |
| 18188554 | Aquatic-plant Protein Combined Restructured Meat and Preparation Method thereof | MORENO, LARK JULIA | 1793 | §103§112 | Final Rejection | — | Pending | Mar 23, 2023 |
| 18075454 | METHOD FOR PREPARING PROTEIN NANOPARTICLE MICROSPHERES | LEBLANC, KATHERINE DEGUIRE | 1791 | §103 | Final Rejection | — | Pending | Dec 06, 2022 |
| 18061585 | Genetically Engineered Bacteria Producing Lacto-N-neotetraose and Production Method Thereof | EIX, EMILY FAY | 1653 | §103 | Non-Final OA | — | Pending | Dec 05, 2022 |
| 17990976 | Application of microbiota-derived plasmalogens to Treatment of Colon Cancer | MAHLUM, JONATHAN DAVIS | 1625 | §103 | Final Rejection | 16d overdue | Pending | Nov 21, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialJiangnan University has 10 pending office actions as of October 2026, spread across 10 art units and 10 examiners.
Nicole Marie Ippolito has the most, with 1 of Jiangnan University's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
